SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

26 Jul 2024 Evaluate
A decent increase of about 25.61% in the sales to Rs. 10632.00 millions was observed for the quarter ended June 2024. The sales figure stood at Rs. 8464.30 millions during the year-ago period.The Total Profit for the quarter ended June 2024 of Rs. 852.70 millions grew from Rs.-333.60 millionsOP of the company witnessed a marginal growth to 1883.90 millions from 432.70 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 10632.00 8464.30 25.61 10632.00 8464.30 25.61 43901.10 34432.20 27.50
Other Income 367.60 266.80 37.78 367.60 266.80 37.78 2020.60 3410.70 -40.76
PBIDT 1883.90 432.70 335.38 1883.90 432.70 335.38 8199.80 4386.00 86.95
Interest 248.80 338.00 -26.39 248.80 338.00 -26.39 1071.00 1158.70 -7.57
PBDT 1635.10 94.70 1626.61 1635.10 94.70 1626.61 7128.80 3157.70 125.76
Depreciation 518.50 503.70 2.94 518.50 503.70 2.94 2052.60 1920.80 6.86
PBT 1116.60 -409.00 -373.01 1116.60 -409.00 -373.01 5076.20 1236.90 310.40
TAX 263.90 -75.40 -450.00 263.90 -75.40 -450.00 1164.00 541.90 114.80
Deferred Tax -10.40 -75.40 -86.21 -10.40 -75.40 -86.21 39.20 154.20 -74.58
PAT 852.70 -333.60 -355.61 852.70 -333.60 -355.61 3912.20 695.00 462.91
Equity 13229.50 11933.20 10.86 13229.50 11933.20 10.86 13229.50 11933.20 10.86
PBIDTM(%) 17.72 5.11 246.61 17.72 5.11 246.61 18.68 12.74 46.63

Piramal Pharma Share Price

148.90 1.45 (0.98%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×